Navigation Links
PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
Date:4/12/2012

ements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, at this point there can be no assurance that PharmAthene's rPA product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans.  Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
4. PharmAthene Reports Third Quarter 2011 Financial and Operating Results
5. PharmAthene Progresses Second Generation rPA Anthrax Vaccine
6. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
7. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
8. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
9. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
10. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
11. PharmAthene Completes $6.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5
... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical applications, ... Healthcare Conference. The conference will be held at the Four ... Bacterin,s chairman and CEO, Guy Cook, and CFO, John ...
... NEWTOWN SQUARE, Pa., Aug. 24, 2011 Kibow Biotech, ... worldwide licensing and marketing agreement with the current licensing ... a patented, 100% natural, probiotic dietary supplement indicated for ... moderate to severe renal failure. Developed by Kibow, Azodyl™ ...
... generated stem cells from one of the most rapidly progressing ... into the condition as it will enable scientists to model ... certain nerve cells die. Scientists, funded with a 300,000 ... a patient diagnosed with one of the most progressive types ...
Cached Biology Technology:Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011 2Kibow Biotech, Inc. Secures $2.4 Million Towards Its Human Clinical Trials by Continued Veterinary Licensing Agreement 2Stem cell study offers hope for Parkinson's patients 2
(Date:10/19/2014)... the last 30 years contributed only marginally to ... time, according to a new study published in ... access is fundamental to development: it brings improvements ... and health," says IIASA researcher Shonali Pachauri, who ... is widely agreed to be an important goal ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... unique partnership between Syracuse University and the Serum Institute ... vaccines for children living in some of the most ... awarded $250,000 to a team of SU researchers led ... College of Arts and Sciences, to develop new oral ...
... America,s health! Water is essential to life, and one ... water safe from pathogens and other waterborne contaminants. Today, ... grants to four universities, one non-profit, and one research ... drinking water contaminants; including the harmful substances produced by ...
... have discovered a gene enhancer, known as HACNS1, that may ... thumb, and possibly also modifications in the ankle or foot ... a paper published in Science on Sept. 5, ... of the existence of human-specific gene enhancers, which are switches ...
Cached Biology News:Syracuse University partners with Serum Institute of India to develop vaccines for children 2Syracuse University partners with Serum Institute of India to develop vaccines for children 3Syracuse University partners with Serum Institute of India to develop vaccines for children 4To your health: EPA announces safe drinking water research 2Gene enhancer in evolution of human opposable thumb 2Gene enhancer in evolution of human opposable thumb 3
... Useful for the determination of digitonin and digoxin. ... EDTA Na 4 and 0.06% NaCl Preparation ... al., Biochem. Biophys. Res. Commun., 19, 755 ... mole of inorganic phosphorus from ATP per min ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
... Centra CL3 series is designed to ... and clinical applications at a reasonable ... includes quick connect rotors and various ... intuitive interface allows you to control ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: